What is Trevi Therapeutics, Inc.'s total net securities (losses)?

Trevi Therapeutics, Inc. (TRVI) reported total net securities (losses) of $0 in Q1 2026.

Trevi Therapeutics, Inc. TRVI Total net securities (losses)

Total net securities (losses) at other companies

JPMorgan ChaseJPM

$64M+273%

BKBK

-$50M—

PNC Financial ServicesPNC

$28M+1,500%

American International GroupAIG

-$130M+50.4%

Fulton FinancialFULT

$0+100%

Cullen/Frost BankersCFR

$0—

Other financials

Income statement

See full

Operating income-$14.9M-30.0%

Net income-$13.2M-27.6%

EPS (diluted)-$0.090.0%

Balance sheet

See full

Cash & equivalents$19.4M+0.2%

Total debt$682.0K-28.7%

Total equity$172.1M+73.1%

Total assets$179.6M+67.8%

Cash flow

See full

Operating cash flow-$16.7M-23.8%

CapEx$102.0K—

Free cash flow-$16.8M—

Valuation

See full

Market cap$2.49B+152%

Returns & leverage

See full

Return on equity-33.6%-9.4pp

Debt / equity0×0.0×

Current ratio24.8×+9.4×

Where this comes from

Reported directly by Trevi Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss.

The official record: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Trevi Therapeutics, Inc.'s total net securities (losses).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Trevi Therapeutics, Inc.'s total net securities (losses)?: Trevi Therapeutics, Inc. (TRVI) reported total net securities (losses) of $0 in Q1 2026.